Aptamer Group Share Price (APTA)

...in drug development.......concluded it's not just a benefit......it's essential as the alternative is the passport to liquidation......I've copied and pasted the best article I've come across......

Importance of AI in Pharmaceutical Drug Development

Pharmaceutical drug development increasingly relies on artificial intelligence (AI) for several key reasons:

Accelerated Drug Discovery

Speed: AI significantly reduces the time required to discover new drugs. Traditional methods can take years, while AI can streamline this process to mere days.

Cost-Effectiveness: By optimizing the discovery process, AI helps lower the costs associated with developing new medications.

Enhanced Clinical Trial Efficiency

Data Management: AI can analyze vast amounts of clinical data quickly, identifying patterns and insights that human researchers might miss.

Predictive Analytics: AI models can predict drug efficacy and potential side effects, improving the design of clinical trials and patient selection.

Improved Regulatory Approval Processes

Streamlined Submissions: AI assists in preparing regulatory submissions by managing complex documentation and ensuring compliance with regulatory standards.

Real-Time Monitoring: AI tools can monitor ongoing trials and post-marketing data, providing insights that can facilitate quicker regulatory decisions.

Summary of AI Benefits in Drug Development

Benefit Description

Accelerated Discovery Reduces time from years to days for new drug discovery

Cost Reduction Lowers overall development costs

Enhanced Data Analysis Analyzes large datasets for insights and trends

Predictive Capabilities Predicts drug efficacy and side effects

Streamlined Regulatory Process Facilitates quicker and more efficient regulatory submissions

AI's integration into pharmaceutical drug development not only enhances efficiency but also fosters innovation, ultimately leading to safer and more effective medications reaching the market faster.

Market Outlook

The last pattern detected was bullish, indicating positive implications. The overall evidence, however, is saying “Watch Out!” but it is not yet pointing to BUY. The share price is still not above the confirmation level and the signal is suggesting to STAY IN CASH, but the chance of a bullish confirmation that will change the signal to BUY is quite high.

"the chance of a bullish confirmation that will change the signal to BUY is quite high"

Wish I could buy some more ....but maxed out.....However does look promising for a tic up sooner than later ... DYOR

.....this site has a fuc?off button as I know someone I'd like to use it on

From the trading update RNS dated 13th May 2024.....

'Following fundraising in August 2023, Aptamer set out three strategic objectives: (1) to achieve EBITDA and cash break-even position within two years, (2) to implement platform process improvements, and (3) to generate marketing data and increase commercial traction by broadening the service offering to the market.'

They'll probably only be about £1.5m out on that forecast! Be nice to know what has gone so wrong in the space of two years for them to fall so short.